Vitamin D and prostate cancer

Christine M. Barnett, Tomasz (Tom) Beer

    Research output: Chapter in Book/Report/Conference proceedingChapter

    1 Citation (Scopus)

    Abstract

    Following epidemiological observations that suggested links between low vitamin D exposure and increased risk of prostate cancer, interest in clarifying a potential role of this steroid hormone in prostate cancer has grown. While the results have been mixed, epidemiologic studies have suggested that severe vitamin D deficiency may increase the risk of clinically important prostate cancer. Laboratory investigation provides clear evidence of the potential of vitamin D receptor (VDR) ligands to induce growth arrest and promote apoptosis in a variety of cancer models. Because there are hundreds of vitamin D responsive genes, multiple mechanisms for these observations have been proposed. Prompted by clear evidence of dose-dependent antitumor effects, efforts to harness this knowledge to improve patient outcomes has focused primarily on the development of high dose calcitriol, often in combination with other anti-neoplastic agents. After encouraging phase II results, the phase III effort failed when excess deaths were reported in the experimental arm of a trial that compared calcitriol with docetaxel to prednisone with docetaxel. In addition to targeting the vitamin D receptor, the two arms of this study differed with respect to the dose, schedule, and dose intensity of the chemotherapy agent and steroids, making definitive conclusions about the potential of vitamin D receptor targeted therapy difficult. No prospective randomized studies aimed at prostate cancer prevention have been reported. Continued efforts to target vitamin D signaling for prostate cancer prevention and treatment are needed in light of the strong preclinical evidence supporting the importance of this signaling pathway. Better understanding of the human prostate cancer's biologic heterogeneity in vitamin D sensitivity may allow for more robust identification of ways in which vitamin D can be harnessed to help men who suffer from this disease.

    Original languageEnglish (US)
    Title of host publicationVitamin D and Cancer
    PublisherSpringer New York
    Pages221-249
    Number of pages29
    ISBN (Print)9781441971876
    DOIs
    StatePublished - 2011

    Fingerprint

    Vitamin D
    Prostatic Neoplasms
    docetaxel
    Calcitriol Receptors
    Calcitriol
    Steroid hormones
    Steroids
    Vitamin D Deficiency
    Chemotherapy
    Prednisone
    Epidemiologic Studies
    Appointments and Schedules
    Genes
    Hormones
    Prospective Studies
    Apoptosis
    Ligands
    Drug Therapy
    Therapeutics
    Growth

    Keywords

    • 125-dihydroxyvitamin D
    • Differentiation
    • Epidemiology
    • Keratinocytes
    • Photoprotection
    • Prevention
    • Prostate cancer
    • Skin cancer
    • Solar UV radiation
    • Vitamin D
    • Vitamin D analogs
    • Vitamin D receptor

    ASJC Scopus subject areas

    • Biochemistry, Genetics and Molecular Biology(all)

    Cite this

    Barnett, C. M., & Beer, T. T. (2011). Vitamin D and prostate cancer. In Vitamin D and Cancer (pp. 221-249). Springer New York. https://doi.org/10.1007/978-1-4419-7188-3-10

    Vitamin D and prostate cancer. / Barnett, Christine M.; Beer, Tomasz (Tom).

    Vitamin D and Cancer. Springer New York, 2011. p. 221-249.

    Research output: Chapter in Book/Report/Conference proceedingChapter

    Barnett, CM & Beer, TT 2011, Vitamin D and prostate cancer. in Vitamin D and Cancer. Springer New York, pp. 221-249. https://doi.org/10.1007/978-1-4419-7188-3-10
    Barnett CM, Beer TT. Vitamin D and prostate cancer. In Vitamin D and Cancer. Springer New York. 2011. p. 221-249 https://doi.org/10.1007/978-1-4419-7188-3-10
    Barnett, Christine M. ; Beer, Tomasz (Tom). / Vitamin D and prostate cancer. Vitamin D and Cancer. Springer New York, 2011. pp. 221-249
    @inbook{d20adcd41bad43e1a2ac513cf552f9d6,
    title = "Vitamin D and prostate cancer",
    abstract = "Following epidemiological observations that suggested links between low vitamin D exposure and increased risk of prostate cancer, interest in clarifying a potential role of this steroid hormone in prostate cancer has grown. While the results have been mixed, epidemiologic studies have suggested that severe vitamin D deficiency may increase the risk of clinically important prostate cancer. Laboratory investigation provides clear evidence of the potential of vitamin D receptor (VDR) ligands to induce growth arrest and promote apoptosis in a variety of cancer models. Because there are hundreds of vitamin D responsive genes, multiple mechanisms for these observations have been proposed. Prompted by clear evidence of dose-dependent antitumor effects, efforts to harness this knowledge to improve patient outcomes has focused primarily on the development of high dose calcitriol, often in combination with other anti-neoplastic agents. After encouraging phase II results, the phase III effort failed when excess deaths were reported in the experimental arm of a trial that compared calcitriol with docetaxel to prednisone with docetaxel. In addition to targeting the vitamin D receptor, the two arms of this study differed with respect to the dose, schedule, and dose intensity of the chemotherapy agent and steroids, making definitive conclusions about the potential of vitamin D receptor targeted therapy difficult. No prospective randomized studies aimed at prostate cancer prevention have been reported. Continued efforts to target vitamin D signaling for prostate cancer prevention and treatment are needed in light of the strong preclinical evidence supporting the importance of this signaling pathway. Better understanding of the human prostate cancer's biologic heterogeneity in vitamin D sensitivity may allow for more robust identification of ways in which vitamin D can be harnessed to help men who suffer from this disease.",
    keywords = "125-dihydroxyvitamin D, Differentiation, Epidemiology, Keratinocytes, Photoprotection, Prevention, Prostate cancer, Skin cancer, Solar UV radiation, Vitamin D, Vitamin D analogs, Vitamin D receptor",
    author = "Barnett, {Christine M.} and Beer, {Tomasz (Tom)}",
    year = "2011",
    doi = "10.1007/978-1-4419-7188-3-10",
    language = "English (US)",
    isbn = "9781441971876",
    pages = "221--249",
    booktitle = "Vitamin D and Cancer",
    publisher = "Springer New York",

    }

    TY - CHAP

    T1 - Vitamin D and prostate cancer

    AU - Barnett, Christine M.

    AU - Beer, Tomasz (Tom)

    PY - 2011

    Y1 - 2011

    N2 - Following epidemiological observations that suggested links between low vitamin D exposure and increased risk of prostate cancer, interest in clarifying a potential role of this steroid hormone in prostate cancer has grown. While the results have been mixed, epidemiologic studies have suggested that severe vitamin D deficiency may increase the risk of clinically important prostate cancer. Laboratory investigation provides clear evidence of the potential of vitamin D receptor (VDR) ligands to induce growth arrest and promote apoptosis in a variety of cancer models. Because there are hundreds of vitamin D responsive genes, multiple mechanisms for these observations have been proposed. Prompted by clear evidence of dose-dependent antitumor effects, efforts to harness this knowledge to improve patient outcomes has focused primarily on the development of high dose calcitriol, often in combination with other anti-neoplastic agents. After encouraging phase II results, the phase III effort failed when excess deaths were reported in the experimental arm of a trial that compared calcitriol with docetaxel to prednisone with docetaxel. In addition to targeting the vitamin D receptor, the two arms of this study differed with respect to the dose, schedule, and dose intensity of the chemotherapy agent and steroids, making definitive conclusions about the potential of vitamin D receptor targeted therapy difficult. No prospective randomized studies aimed at prostate cancer prevention have been reported. Continued efforts to target vitamin D signaling for prostate cancer prevention and treatment are needed in light of the strong preclinical evidence supporting the importance of this signaling pathway. Better understanding of the human prostate cancer's biologic heterogeneity in vitamin D sensitivity may allow for more robust identification of ways in which vitamin D can be harnessed to help men who suffer from this disease.

    AB - Following epidemiological observations that suggested links between low vitamin D exposure and increased risk of prostate cancer, interest in clarifying a potential role of this steroid hormone in prostate cancer has grown. While the results have been mixed, epidemiologic studies have suggested that severe vitamin D deficiency may increase the risk of clinically important prostate cancer. Laboratory investigation provides clear evidence of the potential of vitamin D receptor (VDR) ligands to induce growth arrest and promote apoptosis in a variety of cancer models. Because there are hundreds of vitamin D responsive genes, multiple mechanisms for these observations have been proposed. Prompted by clear evidence of dose-dependent antitumor effects, efforts to harness this knowledge to improve patient outcomes has focused primarily on the development of high dose calcitriol, often in combination with other anti-neoplastic agents. After encouraging phase II results, the phase III effort failed when excess deaths were reported in the experimental arm of a trial that compared calcitriol with docetaxel to prednisone with docetaxel. In addition to targeting the vitamin D receptor, the two arms of this study differed with respect to the dose, schedule, and dose intensity of the chemotherapy agent and steroids, making definitive conclusions about the potential of vitamin D receptor targeted therapy difficult. No prospective randomized studies aimed at prostate cancer prevention have been reported. Continued efforts to target vitamin D signaling for prostate cancer prevention and treatment are needed in light of the strong preclinical evidence supporting the importance of this signaling pathway. Better understanding of the human prostate cancer's biologic heterogeneity in vitamin D sensitivity may allow for more robust identification of ways in which vitamin D can be harnessed to help men who suffer from this disease.

    KW - 125-dihydroxyvitamin D

    KW - Differentiation

    KW - Epidemiology

    KW - Keratinocytes

    KW - Photoprotection

    KW - Prevention

    KW - Prostate cancer

    KW - Skin cancer

    KW - Solar UV radiation

    KW - Vitamin D

    KW - Vitamin D analogs

    KW - Vitamin D receptor

    UR - http://www.scopus.com/inward/record.url?scp=84900111215&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84900111215&partnerID=8YFLogxK

    U2 - 10.1007/978-1-4419-7188-3-10

    DO - 10.1007/978-1-4419-7188-3-10

    M3 - Chapter

    AN - SCOPUS:84900111215

    SN - 9781441971876

    SP - 221

    EP - 249

    BT - Vitamin D and Cancer

    PB - Springer New York

    ER -